Fármacos multifuncionais: monoamina oxidase e α-sinucleína como alvos terapêuticos na doença de Parkinson

Química Nova

Cristian Follmer²  Heleno J. C. Bezerra Netto¹ 

[1] ,Universidade Federal do Rio de Janeiro Centro de Ciências Matemáticas e da Natureza Instituto de QuímicaRio de Janeiro RJ ,Brasil

关键词: monoamine oxidase;    α-synuclein;    Parkinson's disease;   

DOI  :  10.1590/S0100-40422013000200017

来源: SciELO

【 摘 要 】

Parkinson's disease (PD) is a neurodegenerative disorder associated to selective degeneration of dopaminergic neurons caused by an intricate relationship among dopamine metabolism, oxidative stress and α-synuclein fibrillation. Most therapies for PD have focused on dopamine replacement through the use of both monoamine oxidase inhibitors (MAOIs) and dopamine precursor L-dopa. Interestingly, certain MAOIs have a broad spectrum of action including anti-fibrillogenic properties in α-synuclein aggregation. Herein we revisit the chemical properties of MAOIs and their action on important targets associated with PD, notably α-synuclein fibrillation and dopamine metabolism, discussing the strategies associated with the development of multi-target drugs for neurodegenerative diseases.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License